Abstract Affecting more than 5.5 million US citizens and around 44 million people worldwide [1], Alzheimer’s disease (AD) involves the pathological formation and deposition of beta-amyloid plaques in the brain, which slowly disrupt neural connections. However, procedures aiming to reduce amyloid-β have failed to re...